Third Party Funds Group - Sub project
Acronym: INTRABRAIN
Start date : 01.01.2026
End date : 31.12.2029
Oncolytic viruses (OVs) are engineered viruses that selectively infect and destroy tumour cells while stimulating anti-cancer immune responses. They represent a promising immunotherapy strategy against glioblastoma multiforme (GBM), a highly aggressive brain cancer with limited treatment options. With the support of the Marie Skłodowska-Curie Actions programme, the INTRABRAIN project proposes to combine OVs with nanoparticles to create scalable, off-the-shelf therapeutic vaccines. The OVs will be modified to express Interleukin-12 to reverse tumour-induced immunosuppression in the brain of animal GBM models. Researchers will use biodegradable nanomaterials to protect OVs from clearance and intranasal delivery to overcome the blood-brain barrier.
Oncolytic viruses (OVs) are engineered viruses that selectively infect and destroy tumour cells while stimulating anti-cancer immune responses. They represent a promising immunotherapy strategy against glioblastoma multiforme (GBM), a highly aggressive brain cancer with limited treatment options. With the support of the Marie Skłodowska-Curie Actions programme, the INTRABRAIN project proposes to combine OVs with nanoparticles to create scalable, off-the-shelf therapeutic vaccines. The OVs will be modified to express Interleukin-12 to reverse tumour-induced immunosuppression in the brain of animal GBM models. Researchers will use biodegradable nanomaterials to protect OVs from clearance and intranasal delivery to overcome the blood-brain barrier.